SLNSilence Therapeutics
About Silence Therapeutics
Silence Therapeutics (OTCMKTS:SLNCF), (NASDAQ:SLN) specializes in the development of precision-engineered medicines for the treatment of serious diseases with unmet medical needs, focusing on the use of RNA technology to inhibit or "silence" disease-causing genes. The company's innovative approach aims to revolutionize treatment for patients by targeting the root causes of diseases at the genetic level. Silence Therapeutics is actively pursuing a diverse range of projects, including proprietary and partnership-based programs, to develop novel therapeutic agents. The objective of the company is to advance its pipeline of RNA-based therapies to clinical development and bring transformative treatments to patients around the world. Silence Therapeutics is committed to pushing the boundaries of genetic medicine to improve health outcomes for future generations.
What is SLN known for?
Snapshot
Public US
Ownership
1994
Year founded
107
Employees
London, United Kingdom
Head office
1 of 2
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
United Kingdom of Great Britain and Northern Ireland
Produtos e/ou serviços de Silence Therapeutics
- SLN124 for treating thalassemia and myelodysplastic syndrome, targeting TMPRSS6 to regulate iron balance.
- SLN360 aimed at addressing cardiovascular disease by reducing Lipoprotein(a) levels, with potential to lower heart attack and stroke risk.
- SLN500, leveraging a partnership with Takeda to develop siRNA therapies targeting rare genetic diseases.
- RNAi technology platform designed to silence disease-causing genes, offering broad therapeutic applications across various conditions.
- Messenger RNA delivery technology that improves the delivery and effectiveness of RNA molecules, enhancing treatment efficacy.
- Customized siRNA molecules developed for partners, targeting a wide range of diseases, showcasing versatility in gene silencing.
equipe executiva do Silence Therapeutics
- Mr. Iain Gladstone Ross B.Sc., BSc (Hons), C.DIR, CH.DInterim CEO & Chairman of the Board
- Ms. Rhonda L. HellumsExecutive VP, CFO, Secretary & Executive Director
- Dr. Steven J. Romano M.D.Executive VP and Chief Research & Development Officer
- Dr. Marie Wikstrom Lindholm Ph.D.Chief Scientific Officer
- Ms. Gem Gokmen HopkinsHead of IR & Corporate Communications
- Mr. Jaimin B. ShahSVP & General Counsel
- Ms. Gianine EspositoChief Human Resources Officer
- Mr. J.P. GabrielChief Technical Operations Officer
- Mr. Curtis Rambaran M.D.Chief Medical Officer